Skip to main content
Journal of General and Family Medicine logoLink to Journal of General and Family Medicine
. 2020 Dec 22;22(3):152–153. doi: 10.1002/jgf2.413

Massive splenomegaly due to splenic marginal zone B‐cell lymphoma

Kiyoshi Shikino 1,, Masatomi Ikusaka 1
PMCID: PMC8090837  PMID: 33977013

Abstract

A 73‐year‐old man presented with an abdominal mass that gradually swells over 3 months. He denied any subjective symptoms. Physical examination revealed massive enlargement of the spleen—the spleen had crossed the midline and its lower margin extended into the lower abdomen.

graphic file with name JGF2-22-152-g002.jpg

Keywords: lymphoma, splenomegaly


A 73‐year‐old man presented with an abdominal mass that gradually swells over 3 months. He denied any subjective symptoms. Physical examination revealed massive enlargement of the spleen—the spleen had crossed the midline and its lower margin extended into the lower abdomen (Figure 1). Laboratory data were as follows: hemoglobin level, 9.6 g/dL; white blood cell count, 5700/µL with 7% atypical lymphocytes; platelet count, 10.4 × 104/µL; and soluble interleukin‐2 receptor level, 3975 U/mL. The liver function test results were normal. Computed tomography showed massive splenomegaly (Figure 2). Splenic biopsy revealed primary splenic marginal zone B‐cell lymphoma. The patient underwent a successful rituximab monotherapy and recovered.

FIGURE 1.

FIGURE 1

The spleen crossing the midline and its lower margin extending into the lower abdomen

FIGURE 2.

FIGURE 2

Computed tomography showed massive splenomegaly

Splenic marginal zone B‐cell lymphoma occurs in <2% of non‐Hodgkin's lymphomas and presents with splenomegaly or dull abdominal pain. 1 Splenomegaly is “massive” when the spleen is palpable >8 cm below the costal margin. 2 The differential diagnosis of splenomegaly, especially when massive, includes lymphomas, chronic myeloid leukemia, hairy cell leukemia, polycythemia vera, sarcoidosis, Gaucher disease, and infectious diseases. 3 The recognized therapeutic options for splenic marginal zone B‐cell lymphoma are splenectomy, chemotherapy, rituximab alone, or rituximab plus chemotherapy. 4

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

All authors had access to the data and a role in writing the manuscript.

INFORMED CONSENT

We have obtained the consent of the patient for publication.

REFERENCES

  • 1. Arcaini L, Paulli M. Splenic marginal zone lymphoma: hydra with many heads? Haematologica. 2010;95(4):534–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J, editors. Harrison's principles of internal medicine. New York, NY: McGraw‐Hill; 2018. [Google Scholar]
  • 3. Chapman J, Bansal P, Goyal A, Azevedo AM. Splenomegaly. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; [updated August 2020; cited 10 November 2020]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430907/ [Google Scholar]
  • 4. Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2020;31(1):17–29. [DOI] [PubMed] [Google Scholar]

Articles from Journal of General and Family Medicine are provided here courtesy of Wiley

RESOURCES